RevMab

anti-OX40 (human), Rabbit Monoclonal (RM313)

CHF 459.00
In stock
REV-31-1199-00-R100100 µlCHF 459.00
More Information
Product Details
Synonyms TNFRSF 4; Tumor Necrosis Factor Receptor Superfamily Member 4; CD134
Product Type Recombinant Antibody
Properties
Clone RM313
Isotype Rabbit IgG
Source/Host Rabbit
Immunogen/Antigen A peptide corresponding to the C-terminus of human OX40 (CD134).
Application

Immunohistochemistry (IHC): 1:200-1:500 dilution
Western Blot (WB): 1:1000-1:2000 dilution

Crossreactivity Human
Specificity

This antibody reacts to human OX40 (CD134).

Purity Protein A purified.
Purity Detail Protein A affinity purified from an animal origin-free culture supernatant.
Concentration N/A
Formulation Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide.
Isotype Negative Control

Rabbit IgG

Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Accession Number P43489
Declaration Manufactured by RevMab Biosciences.
Shipping and Handling
Shipping BLUE ICE
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

OX40 receptor is a member of the TNFR-superfamily of receptors which is not constitutively expressed on resting naïve T cells. OX40 is a secondary co-stimulatory immune checkpoint molecule. OX40 binds to receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response. OX40 expression can promote viral binding and renders cells permissive for viral entry, productive infection and syncytium formation. Stimulating the receptor can improve the response to a powerful virus vector and may be useful in vaccine development.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.